Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Partnerships Provide Global Foundation For Alvotech

Network Of Deals Gives Company’s Biosimilar Portfolio Worldwide Reach

Executive Summary

A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.

You may also be interested in...



Alvotech Value Rises Again As Portion Of Debt Is Wiped Away

Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.

Alvotech Attacks AbbVie Over Adalimumab

Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.

Alvotech Hits Back Over Humira Trade Secrets Accusations

Alvotech has issued a robust rebuttal of accusations that it obtained AbbVie trade secrets relating to Humira for use in developing its biosimilar adalimumab rival.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel